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Abstract
Background: There is a growing interest in the evaluation of Health Related Quality of Life
(HRQoL) among patients undergoing Renal Replacement Therapy. In Spain, no specific
questionnaire exists for kidney transplant patients. Here we present the Spanish validation of the
first specific HRQoL assessment tool: the kidney transplant questionnaire (KTQ).
Methods: Prospective study of 31 patients on transplant waiting list who received the first kidney.
Patients were evaluated before transplant and after 1, 3, 6 and 12 months, using the KTQ and the
SF-36 Health Survey. Feasibility, validity, reliability, and sensibility to change were evaluated.
Results: Mean time of administration of the KTQ was 12 minutes. Correlation coefficients among
KTQ dimensions range between 0.32 and 0.72. Correlation coefficients of KTQ dimensions with
SF-36 PCS were low (r<0.4), and with SF-36 MCS were moderate-high (r>0.4) except for Physical
Symptom dimension (r = 0.33). Cronbach's Alpha was satisfactory for all KTQ dimensions (Physical
Symptoms = 0.80; Fatigue = 0.93; Uncertainty/Fear = 0.81; Emotional= 0.90) except Appearance
(0.69). Intraclass correlation coefficients ranged between 0.63 and 0.85, similar to those of the
original KTQ version.
Conclusions: Results of validation study show that feasibility, validity, reliability and sensibility to
change of the Spanish version of the KTQ are similar to those of the original version.
Background
The evaluation of Health Related Quality of Life (HRQoL)
in chronic diseases is becoming more and more impor-
tant. The reasons for the importance of HRQoL assess-
ment can be summarized as follows [1]: 1° to determine
the efficacy of medical intervention; 2° to improve the
process of making clinical decisions; 3° to evaluate the
quality of care; 4° to estimate the health care need of the
general population; and 5° to gain a better understanding
of the causes and consequences of the differences in
health. For some authors [2] the assessment of perceived
health status is especially important in the evaluation of
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require information about the effects of a specific disease
on patients, and also of the effect of a specific treatment,
in order to improve its management and the assessment
of the evolution of the patient.
In the Nephrology field, the evaluation of HRQoL
involves: 1st determining the efficiency and effectiveness
of the different forms of renal replacement therapy (RRT)
(hemodialysis, peritoneal dialysis and kidney transplanta-
tion); 2nd evaluating the efficiency and effectiveness of the
different types of other treatments applied to patients with
End Stage Renal Disease (ESRD) (such as rh-EPO treat-
ment, or the different types of immunosuppressive treat-
ments); 3rd follow-up of the evolution of individual renal
patients.
In these areas the evaluation of HRQoL can be another
element of judgement which, taking into account the
point of view of patient, allows a wider vision of the med-
ical care provided to chronic patients. The purpose of
medical intervention in chronic patients, such as ESRD
patients, cannot be to restore health, but to provide a
longer and better life. So, nephrologists who understand
the importance of evaluating HRQoL in patients with
ESRD are numerous [3–7].
The majority of experts in HRQoL evaluation recommend
the use of a specific questionnaire for each disease,
together with a generic instrument, when evaluating the
HRQoL of any type of patients [7,8]. The generic question-
naire allows the comparison of the group of patients
under study in each case, with the general population and
with other groups of patients. In the case of ESRD, it also
allows the evaluation of the effect of the change of RRT
(hemodialysis, peritoneal dialysis and kidney transplant).
The disease specific questionnaire is more accurate in
measuring changes in the evolution of patients, especially
those caused by therapeutic interventions.
On the other hand, the number of ESRD patients bearing
a functioning kidney transplant is growing in Spain, 50.6
patients per million population in 1999 [9]. In Spain,
although there are specific HRQoL questionnaires for
patients on dialysis treatment which are validated, as is
the case of the Kidney Disease Questionnaire-KDQ [10], and
of the Kidney Disease Quality of Life Instrument-KDQOL
[11], there is no HRQoL assessment tool for evaluating
kidney transplant bearers in a more detail and adapted to
the specific characteristics of these patients.
This study, therefore intends to provide a HRQoL assess-
ment instrument appropriate for routine use in any Neph-
rology unit: the Spanish version of the Kidney Transplant
Questionnaire (KTQ). This questionnaire will be useful in
the clinical follow-up of kidney transplant patients, and in
the evaluation of the different types of immunosuppres-
sive treatments that they receive. Results of the assessment
of psychometric features of this specific HRQoL question-
naire are presented in this article.
Methods
This is a longitudinal prospective study, including 54
ESRD patients undergoing chronic dialysis (hemodialysis
or peritoneal dialysis) who entered the kidney transplant
waiting list during the years 1999 and 2000. Of these
patients, 42 received a first kidney transplant at the "Hos-
pital Central de Asturias" before the end of the year 2000.
Transplant patients who were assessed at all stages of the
follow-up, during the first year of evolution (N = 31), were
included in this study of evaluation of the psychometric
features of the Spanish version of the Kidney Transplant
Questionnaire (KTQ). The excluded patients (N = 11) had
similar sociodemographic and clinical characteristics to
those included.
Patients were recruited at the moment of the pre-trans-
plant examination, when they were included on the kid-
ney transplant waiting list.
Patients were interviewed by the medical doctor in charge
of the study, or by one of two suitably trained nephrology
nurses. In all the cases, the interview was conducted in a
relaxed atmosphere.
At the moment of inclusion, the first interview was carried
out, starting with the sociodemographic and clinical data
collection record: patient identification data; age; sex;
level of education in four groups: level 0 (no schooling),
level 1 (primary studies completed), level 2 (secondary
studies completed) and level 3 (university studies com-
pleted); Socioeconomic level, deduced from the monthly
family income in three groups: level 1 (less than 900 €/
month), level 2 (between 900 and 1,800 €/month) and
level 3 (more than 1,800 €/month); living conditions
(patients living alone, with at least one person, or in a
nursing home); work status (patients who are working or
who are not actively working); renal disease diagnosis
(Nephrosclerosis-NE; Diabetes Mellitus-DM; Glomeru-
lonephritis-GN; Interstitial Nephritis-IN; Polycystic Kid-
ney Disease-PK; Others, which included an unknown
cause); date of initation of renal replacement therapy
(dialysis); functional status measured by Karnofsky Scale
score; serum analytics including hemoglobin, creatinine
and albumin corresponding to the date of interview; and
a detailed comorbidity index [12] which includes 24 dis-
eases that are defined by specific criteria, each disease hav-
ing five possible scores (from zero to four), depending on
whether the disease is absent, present but not producing a
limitation of physical activity, or present and producing aPage 2 of 9
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The addition of the score of each item gives a global score
that ranges between theoretical values of 0 and 96.
Later in the interview the SF-36 Health Survey (SF-36) and
the first part of the KTQ were carried out by the inter-
viewer. Afterwards the second part of the KTQ was self-
completed with a previous explanation given by the doc-
tor. The investigator checked that patients have fulfilled
all the items before the end of the interview.
The interview was repeated every 6 months while the
patients remained on the transplant waiting list, until they
received a kidney transplant. From that moment, the
interview was carried out at the first, third, sixth and
twelfth month after the date of transplantation. At each
stage the following data was collected: age; level of educa-
tion, socioeconomic level, living conditions and work sta-
tus, using the same groups as in the first interview; date of
renal transplantation; functional status measured by
Karnofsky Scale score; serum analysis including hemo-
globin, creatinine and albumin, and also creatinine clear-
ance and proteinuria; comorbidity index; episodes of
infection occurring since the last interview, their duration
and severity according to clinical criteria; episodes of ini-
tial allograft dysfunction (measured by the number of
hemodialysis sessions needed); episodes of acute rejec-
tion and of surgical problems related to the kidney trans-
plant; number and duration (in days) of hospital
admissions during the period of each interview; and the
variations of the immunosupressor treatment and of the
doses administered to patients since the last interview.
The SF-36 Health Survey (SF-36) is a generic HRQOL
assessment tool [13,14] appropriately translated and vali-
dated in Spain [15], which includes eight dimensions (PF-
Physical Functioning; RP-Rol Physical; BP-Bodily Pain;
GH-General Health; VT-Vitality; SF-Social Functioning;
RE-Rol Emotional; MH-Mental Health) and two summary
scores (PCS-Physical Component Summary; and MCS-
Mental Component Summary). Every dimension of the
SF-36 can be scored from 0 (the worst HRQOL) to 100
(the best HRQOL). A standardization of these scores was
applied, according to age and gender, using the Spanish
population normative data [16], obtained from a study
carried out over a random stratified sample of 9,151 sub-
jects of the general population who answered the ques-
tionnaire. A standardized score over 0 indicates better
HRQOL than that of the general population of the same
age and gender; and a score under 0 indicates worse
HRQOL [12].
The Kidney Transplant Questionnaire was developed by
Laupacis et al. [17]. It is a HRQOL assessment instrument
specific for kidney transplant bearers. Previously, the
same authors had developed a specific questionnaire for
dialysis patients: the Kidney Disease Questionnaire
(KDQ) [10], but they did not develop the KTQ as an adap-
tation of the KDQ for kidney transplant. They thought
that the clinical situation of kidney transplant patients
was very different to that of dialysis patients, and that it
required a new questionnaire. The original instrument has
25 items grouped in five dimensions: Physical symptoms
(6 items), Fatigue (5 items), Uncertainty/fear (4 items),
Appearance (4 items) and Emotional (6 items). The first
dimension (Physical symptoms) is patient specific. It
includes the six main symptoms for each patient, and it is
used in the individual follow-up of the patient. All the
items have a likert scale with 7 possible answers. In the
validation study of the original version of the KTQ, the
internal consistency (measured by the Cronbach's alpha)
for each dimension was 0.76 (physical symptoms), 0.94
(fatigue), 0.63 (uncertainty/fear), 0.61 (appearance), and
0.80 (emotional). Construct validity was assessed by
means of the correlation coefficients between the KTQ
dimensions (r coefficient between 0.19 and 0.67) and cor-
relation coefficients between the KTQ dimensions and
other HRQOL assessment instruments. Reproducibility
was analyzed in the group of patients remaining clinically
stable between months 6 and 12 after kidney transplanta-
tion, using the Intraclass Correlation Coefficients, which
were high (between 0.82 and 0.91). Sensibility to change
was also quite adequate: the scores of the dimensions,
except that of "Appearance", improved after 6 months
from transplantation compared to pre-transplantation
scores. The English original version of the KTQ was trans-
lated into Spanish by two independent professional trans-
lators. English back-translations from the Spanish were
done by a professional translator unaware of the original
version. Both English versions were compared, and where
needed, modifications to the Spanish versions were made.
The preliminary version of the questionnaire was
reviewed by a group of nephrologists and nurses of dialy-
sis units who approved the final version of the Spanish
questionnaire.
Statistical analysis
All the variables collected were entered in a data base for
the statistical analysis carried out with the SPSS 7.5 statis-
tical package. The statistical analysis was carried out in
steps: feasibility, validity, reliability and change
sensibility.
Feasibility
questions not answered or not understood were analyzed,
together with the time required to complete the
questionnaire.Page 3 of 9
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construct validity was examined studying the correlation
coefficients between the KTQ dimensions. Concept valid-
ity was studied analyzing the correlation coefficients
between the scores of the KTQ dimensions and the scores
of the two Component Summaries of the SF-36 (PCS and
MCS), the seric creatinine and hemoglobin, the comor-
bidity index score, the functional status, the number of
infections, and the number and duration of hospital
admissions; Pearson correlation coefficients were
employed when variables were normally distributed, and
Spearman coefficients if they were not. Associations of
scores of the KTQ dimensions with episodes of initial allo-
graft dysfunction, acute rejection and surgical problems
related to kidney transplantation were also assessed, using
the Student's T test. Construct and concept validity were
evaluated with the data corresponding to six months after
kidney transplantation.
Reliability
Internal consistency was studied calculating the Cron-
bach's Alpha. This coefficient is acceptable when it is
above 0.7, following Nunnally's criteria [18]. Test-retest
reliability was assessed by means of the Intraclass Correla-
tion Coefficient.
Change Sensibility
the change in scores of the KTQ dimensions was studied
with the data of the first and the last follow-up interview,
using the Student's T test for paired samples. This change
was also studied by dividing patients into two groups:
patients who answered the general health evolution ques-
tion as "feeling better", and patients who answered as
"feeling the same or worse".
The Effect Size of "to have a functioning kidney transplant
during one year" was also assessed for each dimension of
the Spanish KTQ, dividing the difference between the
mean score in the first interview and that of the last one
by the standard deviation of the mean score in the first
interview [19]. The Effect Size is considered as small if it is
under 0.2; moderate if it is near 0.5; and large if it is over
0.8.
Results
Out of 42 patients who had received the kidney transplant
before the end of the year 2000, 31 completed all the per-
sonal interviews at the required times durign the follow-
up year. This is the sample used for the study of validation
of the Spanish version of the Kidney Transplant Question-
naire (KTQ) that is presented here.
In Table 1 the sociodemographic, clinical and analytical
data are presented, all data collected at the beginning of
the study, and also in month 12 of the follow up for some
variables. It can be observed in the table that, in the stud-
ied sample, the median age was 51 years and there were
more males than females (21 men versus 10 women). As
Table 1: Sociodemographic and clinical characteristics of the sample (N = 31)
Sociodemographic and clinical variables at start of follow-up (1 month postransplantation)
Median age (Interc. range) 51 years (38
– 57)
Male gender (%) 21 males
(68%)
Economic level (%) <900 €/month (38%) 900–1,800 €/m. (48%) >1,800 €/m. (14%)
Educational level (%) Primary (43%) Secondary (38%) University (19%)
Living conditions (%) Alone (10.3%) In family (86.2%) Institution (3.4%)
Work status (%) Active working (4%) No active working (96%)
Main diagnosis (%) NE
(7.1%)
DM
(17.9%)
GN
(25%)
IN
(14.3%)
PK.
(17.9%)
Other
(17.9%)
Variables Evolution 1st month 
postrasplan
tation
12th month 
postrasplantat
ion
Karnof. Scale. Median (int. range) 90 (80 – 100) 100 (90 – 100)
Comorbidity Index (Mean ± SD) 3.24 ± 2.25 3.45 ± 2.31
Hemoglobina grs/dL (mean ± SD) 11.69 ± 1.19 13.75 ± 13.50 **
SCr mgr/dL (mean ± SD) 1.54 ± 0.50 1.46 ± 0.43
ClCr mL/min (mean ± SD) 66.80 ± 20.18 76.42 ± 25.50 *
Albumin grs/dL (mean ± SD) 3.87± 0.34 5.05 ± 6.27
Proteinuria grs/24 h (mean ± SD) 0.38 ± 0.27 0.37 ± 0.35
Main Diagnosis: NE-Nephrosclerosis; DM-Diabetes Mellitus; GN-Glomerulonephritis; IN-Interstitial Nephritis; PK-Policystic Kidney Disease; Other-
other diagnosis Scr: seric creatinine ClCr: creatinine clearance * Paired Student t test. P < 0.05 ** Paired Student t test. P < 0.01Page 4 of 9
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did not work during their treatment with chronic dialysis
and who remained in that situation during the first year
after having received the kidney allograft. More than 40%
of patients had elementary studies (no patient without
studies) and most of the patients did not live alone and
had an medium economic level (between 900 and 1,800
€ monthly). As far clinical data, it is observed that the
most frequent diagnosis of renal disease was glomeru-
lonephritis. According to Karnofsky Scale score patients
demonstrated a good functional state (median = 90)
which at the end of the study was even better (median =
100), although they had a mean comorbidity index close
to 3 points or diseases at the start of the follow up (3.24 ±
2.25 first postransplant month). The comorbidity index
hardly varied at the different stages of the study: 3.58 ±
2.18 at the third postrasplant month; 3.52 ± 2.47 at the
sixth postrasplant month; and 3.45 ± 2.31 at the twelfth
month of follow up. The analytical figures with statisti-
cally significant improvement, comparing the start of the
study with the end, were the hemoglobin and the creati-
nine clearance.
Other variables whose evolution was studied during
patient follow-up are not included in Table 1, are
described next. Patients who had suffered initial allograft
dysfunction were only 7 (22.6%); acute rejection, 4
patients (12.9%); and surgical problems related to the
kidney transplant, 5 patients (16.1%). With respect to the
hospital admissions throughout the follow-up, 14
patients (45.2%) were admitted at least once; for these
patients, the mean number of hospitalized days was 10.6
± 7.6 days. The number of patients who suffered some
infection during the follow up period was very low at all
stages: 2 patients (6.5%) in the first postrasplant month;
5 patients (16.1%) during the second and third month; 6
patients (19.3%) in months 4, 5 and 6; and 2 patients
(6.5%) in the last interval between visits. As a whole, 12
patients (38.7%) suffered some infection during the fol-
low up.
All the patients self-completed the Spanish version of KTQ
at all stages of the study, in a mean time of 11.9 ± 1.7 min-
utes (between 10 and 20 minutes). Although in all cases
they responded to all items of the questionnaire, there
were two questions with problems of understanding in a
small percentage of the cases. These items were question
14 (2 patients – 6.5%) and question 15 (4 patients –
13%). Question 14 asks with what frequency, during the
two last weeks, the patient has felt "anxious", this is a con-
cept that the patients mentioned said they did not under-
stand well. Question 15 refers to the "fear or panic of
rejection". This made the patients doubt whether the
interviewer was talking about feeling rejected by society
(by being a kidney transplanted patient) or the physical
rejection of the kidney allograft.
In Table 2 the mean scores, and the corresponding stand-
ard deviations, of the dimensions of the KTQ and the SF-
36 questionnaires are presented for the different stages of
evolution. As can be observed, the scores increased
throughout the follow up. In some cases, the increase is
clear ("Physical Symptoms", "Fatigue" and "Uncertainty/
Fear") and in other cases the increase is less important
(Appearance and Emotions). Also, for the two component
summary scores of the SF-36 questionnaire, one showed a
clear increase (Physical Component Summary or PCS)
and the other did not present such an obvious increase
(Mental Component Summary or MCS).
The correlation coefficients among the dimensions of the
KTQ, which evaluate the construct validity, are shown in
Table 3. As can be observed, the coefficients ranged
between the minimum of 0.32 obtained for "Fatigue" and
Table 2: Evolution of the scores of the HRQoL questionnaires: Kidney Transplant Questionnaire and SF-36 Health Survey (N = 31)
Mean Scores (± standard deviation)
KTQ Month 1 Month 3 Month 6 Month 12
Physical Symptoms 5.10 ± 1.44 5.21 ± 1.52 5.23 ± 1.42 5.79 ± 1.49
Fatigue 5.71 ± 1.20 5.93 ± 1.22 5.89 ± 1.26 6.12 ± 1.18
Uncertainty / fear 5.21 ± 1.47 5.59 ± 1.40 5.47 ± 1.41 5.76 ± 1.21
Appearance 6.04 ± 1.01 5.89 ± 1.24 5.82 ± 1.15 6.20 ± 0.98
Emotions 5.88 ± 1.19 6.00 ± 1.18 5.69 ± 1.17 6.03 ± 1.04
SF36 Month 1 Month 3 Month 6 Month 12
PCS 47.24 ± 9.21 49.72 ± 8.74 51.14 ± 6.48 51.09 ± 8.19
MCS 53.89 ± 11.91 53.00 ± 11.55 51.10 ± 11.73 52.94 ± 10.71
PCS: Physical Component Summary; MCS: Mental Component SummaryPage 5 of 9
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tainty/Fear" and "Emotions", being, in most of the cases,
moderate. Concept validity, measured by the correlation
coefficients between the KTQ and the SF-36 Health Survey
dimensions and some clinical variables, is also presented
in Table 3. The coefficients for the dimensions of the SF-
36 were positive in all the cases. The coefficients between
the KTQ dimensions and the mental component sum-
mary (MCS) score were moderate-high in all the dimen-
sions, being superior to those observed for the physical
component summary (PCS) score, that turned out to be
low (< 0.4).
The correlations with comorbidity index turned out to be
positive and of a low degree. In general, the correlations
of the seric hemoglobin were positive, although of a low
degree. The seric creatinina correlated negatively,
presenting low and moderate coefficients in some cases
("Fatigue" and "Emotions"). For the Karnofsky's Scale, the
correlation coefficients were low, being higher for the
dimensions of the KTQ that covers the physical area
("Physical Symptoms" and "Fatigue") than for those of
the mental area ("Uncertainty/Fear", "Appearance" and
"Emotions"). The number of infections appearing from
the date of the kidney transplantation to month six of the
follow up, maintained low degrees of correlation with the
scores of the dimensions of the KTQ. These correlations
were surprisingly positive in the physical dimensions
("Physical Symptoms" and "Fatigue"), and negative in the
mental dimensions ("Uncertainty /Fear", "Appearance"
and "Emotions"), as had been hypothesized. The number
of hospital admissions and days of hospital stay corre-
lated negatively, with low coefficients, with the scores of
the KTQ dimensions, except for the "Uncertainty /Fear"
dimension. This dimension showed a moderate correla-
tion with the days of hospital admission. There was no
statistically significant association between the scores of
the KTQ dimensions and the variables of "initial dysfunc-
tion of the graft", "acute rejection" and "surgical problems
associated to the kidney transplant". The only association
found was for the score of the "Fatigue" dimension that
turned out to be lower for those patients with surgical
problems (4.84 ± 1.94 versus 6.08 ± 1.01).
Reliability was studied using the Cronbach's Alpha and
the Intraclass Correlation Coefficient, which appears in
Table 4. Cronbach's Alpha coefficients were over 0.7 for
all the dimensions except for the "Appearance" dimen-
sion (0.69). Intraclass Correlation Coefficients were also
over 0.7 except for two dimensions: "Physical symptoms"
(0.63) and "Appearance" (0.67).
The changes in the scores obtained in the KTQ dimen-
sions between the first and last interview of the follow up,
appear in Table 5, along with the Effect Size coefficients
for each. As can be seen, the mean scores improved,
throughout the first year of evolution, with a statistical sig-
nificance in the "Physical Symptoms", "Fatigue" and
"Uncertainty/Fear" dimensions; however, they did not in
the other two: "Appearance" and "Emotions". The Effect
Size of "to have a functioning kidney transplant during
one year" calculated for each dimension was only small,
except for the "Physical Symptoms" dimension. That
same change was also studied by separating the patients
who, in the question regarding evaluation of general state
of health had affirmed they felt better, from those that had
said they felt the same or worse. This way it was verified
that, for the group of patients who had affirmed they felt
better, the effect size was moderate for most dimensions
(Physical Symptoms = 0.82; Fatigue = 0.76; Uncertainty /
Fear = 0.53; Appearance = 0.59) with the exception of the
"Emotions" dimension, which hardly varies during the
follow up (Emotions = 0.03).
Table 3: VALIDITY: Correlation Coefficients among the KTQ 
dimensions and between the KTQ dimensions and other variables 
at 6th month postransplantation (N = 31)
PS F U/F A E
Physical Symptoms (PS)
Fatigue (F) .52
Uncertainty / Fear (U/F) .34 .64
Appearance (A) .54 .32 .34
Emotions (E) .46 .68 .72 .59
PCS .28 .24 .11 .25 .017
MCS .33 .60 .81 .39 .78
Comorbidity Index .28 .06 .07 .25 .20
Seric Hemoglobine -.07 .12 .24 .14 .38
Seric Creatinine -.19 -.54 -.25 -.12 -.35
Karnofsky Scale .31 .23 -.02 .20 .22
Number of Infections .04 .12 -.22 -.12 -.08
Number Hosp. Admissions -.05 -.02 -.18 -.10 -.19
Number Hosp. days -.06 -.09 -.46 -.05 -.19
PCS: Physical Component Summary; MCS: Mental Component 
Summary
Table 4: RELIABILITY: Cronbach's alpha coefficient and 
Intraclass Correlation Coefficient (ICC) (N = 31)
Cronbach's Alpha ICC
Physical Symptoms 0.80 0.63
Fatigue 0.93 0.82
Uncertainty / Fear 0.81 0.81
Appearance 0.69 0.67
Emotions 0.90 0.85Page 6 of 9
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The psychometric properties of the Kidney Transplant
Questionnaire (KTQ) evaluated in the present article have
proven to be satisfactory and so allow the recommenda-
tion of the use of this questionnaire in clinical practice.
This is the first specific instrument, translated and
validated in the Spanish language, for the measurement of
the HRQoL of patients bearing a functioning kidney
transplant.
The sample of the present study was formed through the
prospective recruitment of 54 patients at the moment they
were included on the kidney transplant waiting list. 42 of
them subsequently received a kidney allograft. A possible
skew is that out of the 42 patients included at first, 11 were
excluded because they had not completed all the inter-
views at each of the stages required. Nevertheless, the
excluded patients had similar sociodemographic and clin-
ical characteristics to those included. The sample size of
studies evaluating the psychometric properties of specific
HRQoL assessment instruments, as is the case of the
present study, can never reach the magnitude of the vali-
dations of generic instruments, given the shortage of
patients available with a certain disease. The study of val-
idation of the original version of the Kidney Transplant
Questionnaire [17] was carried out with a sample of only
26 kidney transplant patients. The sociodemographic and
clinical characteristics of the included patients were simi-
lar to those of any other study previously carried out with
patients who had received a kidney allograft [12]. Also,
the incidence of adverse post-transplant events (initial
dysfunction of the graft, acute rejection and/or surgical
problems related to the transplant) were within the limits
that are observed in other series of kidney
transplantations.
The feasibility of the questionnaire is good, as is shown by
the low number of items not answered or not understood
by the interviewees, and also by the average time of
administration of only 12 minutes. The short time
required makes the questionnaire suitable for everyday
clinical use, being no greater than that of other question-
naires in common use, such as the SF-36 Health Survey. It
should also be borne in mind that, in most cases, the
questionnaire was self-completed after brief instructions
that were unnecessary in subsequent interviews, further
facilitating its incorporation in transplant unit routine.
As was shown, the scores of the KTQ dimensions
increased throughout the follow up, indicating improve-
ments in the HRQoL of patients, mainly in the physical
area, as had been hypothesized. This improvement in the
physical area is better determined by the change in the
scores of the KTQ, than by the physical component sum-
mary (PCS) of the SF-36. In fact, in the "Physical Symp-
toms" dimension of the KTQ the change between the
basal and the last stage is of 0.69 points. This change in
score is over the limit of 0.5 points that sets out "clinically
outstanding" for dimensions constructed on Likert scales
of 7 answers. However, in the case of the PCS, the change
is hard to evaluate since it is within the margins of the
expected average (50± 10), and no other reference exists.
It can also be concluded that the KTQ provides more
information than the SF-36. This is shown if we take into
account the fact that the evolution of the scores in "Uncer-
tainty /Fear" is centered on the evaluation of emotional
problems (anxiety or fear) of the kidney transplanted
patients, which are not included in the mental compo-
nent summary (MCS) score of the SF-36.
The correlation coefficients between the dimensions of
the KTQ were moderate, conferring the instrument an
adequate construct validity. The fact that three of the coef-
ficients turned out to be smaller than 0.4 is probably due
to the large number of aspects of the kidney transplant
that the questionnaire includes.
The positive correlation coefficients found between the
dimensions of the KTQ and the summary components of
the SF-36, demonstrate that both instruments evaluate the
same concept. Nevertheless, the correlations with the
physical component of SF-36 (PCS) were discrete, lower
than 0.4 in all cases. It is quite likely that the KTQ meas-
Table 5: Differences between mean scores at start and at the end of follow-up: Effect Size. (N = 31)
Differences between mean scores at start and at the end of follow-up
1st month mean ± 
S.D
12th month mean 
± S.D
Mean difference p Effect Size
Physical Symptoms 5.10 ± 1.44 5.79 ± 1.49 0.68 ± 1.54 0.026 0.48
Fatigue 5.71 ± 1.20 6.12 ± 1.18 0.41 ± 1.02 0.046 0.34
Uncertainty / Fear 5.21 ± 1.47 5.76 ± 1.21 0.55 ± 1.38 0.043 0.37
Appearance 6.04 ± 1.01 6.20 ± 0.98 0.17 ± 1.11 0.42 0.17
Emotions 5.88 ± 1.19 6.03 ± 1.04 0.15 ± 1.12 0.49 0.12Page 7 of 9
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has already been explained.
Regarding the correlation of KTQ dimensions with other
variables collected in the study, the associations always
followed the hypothesized direction, except for the
comorbidity index. Thus, the correlations with the seric
hemoglobin were in general positive, as well as the corre-
lations with the Karnofsky's Scale. This is the logical direc-
tion of the association: the greater the seric hemoglobin or
the better the functional state is, the better the HRQoL
evaluated by the KTQ will be. Also the correlation of the
dimensions of the KTQ with the figure of seric creatinine
confirms what was expected: the higher the seric creati-
nine is, the worse the HRQoL will be. It should not be sur-
prising that the association with the number of infections
is slightly positive in some dimensions and negative in
others, since the infections suffered were not serious,
being taken care of in the preclinical period in most cases.
In our hospital protocols for early detection of antigene-
mia for different virus (CMV, HerpesVirus...) and for the
taking of biological specimens for cultures are followed.
The correlation with the comorbidity index is confusing.
Although it should follow a negative association, that is to
say the greater comorbidity is, the worse HRQoL should
be, it follows a positive tendency. The explanation may be
that the patients already had the comorbidity when
undergoing dialysis, and probably these are the patients
who are most likely to notice an improvement in their
quality of life following the transplant. Probably the slight
variations of the index from the beginning of the follow
up also influence the absence of correlation: 17 patients
had the same, in 6 it diminished, and in 7 it increased
during the first six months. The correlation coefficients
calculated for the hospital admissions and days of hospi-
tal stay followed the negative sign which had been
hypothesized: the greater the number of admissions and/
or days, the smaller the score in the dimensions of the
KTQ was, that is to say, the worse the HRQoL. The fact that
associations between the scores of the KTQ dimensions
and the initial allograft dysfunction, the acute rejection
and surgical problems, were not found is not surprising if
we take into account the low number of patients who
showed adverse effects after transplantation.
Cronbach's alpha coefficients confer the instrument eval-
uated a suitable Reliability even for their use in the indi-
vidualized follow-up of the kidney transplanted patients.
Also the Intraclass Correlation Coefficients calculated for
the Spanish version of the KTQ are very good, being
higher to those of the original version [17] in three dimen-
sions ("Fatigue", "Uncertainty/Fear" and "Emotions"),
and lower in two dimensions ("Symptoms" and
"Appearance").
For the evaluation of sensibility to change of the original
version of the KTQ [17], the pre-transplantation scores
were compared with those obtained at 6 months after
transplantation. However, the use of a questionnaire
adapted to patients with a functioning kidney transplant
does not seem absolutely correct applied to other groups
of different patients, as is the case of patients undergoing
hemodialysis. Thus, in the present study the changes in
the scores from month one to month twelve were used. It
was hypothesized that throughout the first year after
transplantation, the HRQoL would improve. The hypoth-
esis was confirmed, obtaining improvements in all the
dimensions, which were statistically significant in three of
the cases. The effect size of "to have a functioning kidney
transplant during one year" in the KTQ dimensions was
small except for the "Physical Symptoms" dimension, that
turned out to be moderate. Nevertheless, selecting only
the patients who in the question regarding the overall
change in their state of health (SF-36) had affirmed they
felt better, it was verified. For these patients the Effect Size
was moderate, except for the "Physical Symptoms"
dimension that was high, and for the dimension "Emo-
tions", that was very small.
Conclusions
The feasibility, validity, reliability and sensibility to
change of the Spanish version of the Kidney Transplant
Questionnaire are therefore similar to those of the origi-
nal instrument. Thus, a specific HRQoL assessment instru-
ment is now available in the Spanish language. This
instrument will be useful for use in the individual evalua-
tion of patients with end-stage renal disease who receive a
kidney transplant, and also for the evaluation of the dif-
ferent types of inmunosupresor therapies and other types
of therapies which influence the evolution of the kidney
transplant.
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